Analysis Vallon Pharmaceuticals, Inc. (VLON)
6/1/2024
Analysis of Vallon Pharmaceuticals, Inc. (VLON)
Vallon Pharmaceuticals, Inc. is currently showing a downward trend based on the recent data. The closing prices have been decreasing over the past few days, with the RSI indicator hovering around 34-37, indicating a slightly oversold condition.The MACD indicator is also negative, suggesting a bearish momentum in the stock. The Moving Average (MA) indicator is below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), further confirming the bearish trend.
Overall, based on the technical indicators, Vallon Pharmaceuticals, Inc. seems to be in a bearish phase, and investors may want to exercise caution or consider short-term trading strategies until a reversal in the trend is observed.
Balance Sheet
These are balance sheets. Here are the conclusions based on the provided data:1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,583,000,000.
2. Current assets fluctuate from year to year, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $209,017,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $290,437,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2023 at $62,146,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There is a significant amount of debt in the company's capital structure, both short-term and long-term.
8. The company has been investing in machinery, furniture, and equipment over the years.
9. Retained earnings have been negative in some years, indicating losses or dividend payouts exceeding profits.
10. The company has been maintaining a significant amount of cash and cash equivalents on hand.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
In terms of stock statistics, there is a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has been trading within a range over the past 52 weeks.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with high price to book and price to sales ratios.
The stock price summary includes moving averages, 52-week high and low prices, and the percentage change over the past year.
Dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics, as well as details on past splits.
Income statement 💸
Here are the revenue figures for the past four fiscal years:- Fiscal Year 2020: $274,515,000,000
- Fiscal Year 2021: $365,817,000,000
- Fiscal Year 2022: $394,328,000,000
- Fiscal Year 2023: $383,285,000,000
From these numbers, we can observe the following trends:
1. There was a significant increase in revenue from FY 2020 to FY 2021, indicating strong growth.
2. The revenue continued to grow in FY 2022, reaching the highest point in the four-year period.
3. In FY 2023, there was a slight decrease in revenue compared to the previous year, but it still remained higher than the FY 2020 figure.
Overall, the company has shown a positive revenue trend over the past four years, with substantial growth from FY 2020 to FY 2022.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a potential growth compared to the EPS of $6.10 for the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for both the upcoming quarters and fiscal years.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The estimated average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company is expected to experience a moderate growth rate in the near term, with a slightly higher growth rate projected for the next year. However, compared to the past 5 years, the growth rate is expected to slow down over the next 5 years.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of VLON
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
